Pfizer gets Complete Response Letter for trastuzumab biosimilar

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Pfizer Inc. announced it has received a Complete Response Letter from FDA in response to the Biologics License Application for the company’s proposed trastuzumab biosimilar. In the CRL, FDA highlighted the need for additional technical information.

The additional requested information does not relate to safety or clinical data submitted in the application, the company said. Pfizer said it’s working closely with FDA to address the contents of the letter.

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login